ClinicalTrials.gg
CompletedNCT00036270TEAMUpdated Oct 28, 2015Results posted

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

A Phase 3 interventional study of exemestane (Aromasin) and tamoxifen + exemestane in Breast Neoplasms, sponsored by Pfizer. Completed at 179 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,779
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.

Enrollment
Largest of 101
9,779 · median 123
Started
2001
with 7 others
Phase 3
34 of 103
5 open now
Registered
6th of 103
by date
Lead sponsor
9 of 103
Pfizer

Among the 103 studies testing exemestane in Breast Neoplasms, this one has the largest enrollment of the 101 interventional ones that give a count, is one of 8 that started in 2001, is one of 34 in phase 3, and was the 6th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About exemestane

exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing exemestane in Breast Neoplasms, or all of them as a file.
02

Study summary

To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer.

This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or chemotherapy, if indicated.
  • Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.

Exclusion criteria

Exclusion Criteria:

  • Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:
  • Inflammatory breast cancer
  • Histologically positive supraclavicular nodes
  • Ulceration/infiltration of local skin
  • chemotherapy
  • Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion
  • ER and PR negative primary tumor or ER/PR unknown status.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9,779 participants (actual)

Study arms

  • Experimental
    exemestane

    Drug: exemestane (Aromasin)

  • Experimental
    tamoxifen + exemestane

    Drug: tamoxifen + exemestane

Interventions

  • exemestane, orally, 25 mg, for 5 years

    Also known as: aromasin

  • Drugtamoxifen + exemestane

    Drug pages: Tamoxifen · Exemestane

    tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years

    Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.

    Time frame: Baseline (Month 0) up to 2.75 years

  2. Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years

    Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.

    Time frame: Baseline (Month 0) up to 5 years

Secondary outcomes

  1. Number of Events for Overall Survival (OS)

    Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.

    Time frame: Baseline (Month 0) up to 5 years

  2. Time to New Primary Breast Cancers

    New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).

    Time frame: Baseline (Month 0) up to 5 years

  3. Number of Events for Time to Relapse

    Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.

    Time frame: Baseline (Month 0) up to 5 years

  4. Number of Participants With New Primary Non-breast Cancers

    Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.

    Time frame: Baseline (Month 0) up to 5 years

07

Results

Posted Dec 4, 2009
Limitations and caveats
Overall Survival was reported as number of events which otherwise reported as time.

Participant flow

Randomized to Study Treatment
Participant flow — Randomized to Study Treatment
MilestoneExemestaneTamoxifen Followed by Exemestane
Started49044875
Completed48984868
Not completed67
Withdrew: Withdrawal by subject67
Study Treatment to 5 Year Report
Participant flow — Study Treatment to 5 Year Report
MilestoneExemestaneTamoxifen Followed by Exemestane
Started48984868
Treated48524814
Completed23331380
Not completed25653488
Withdrew: Ongoing1081736
Withdrew: Disease- free survival (dfs) event507447
Withdrew: Adverse event501782
Withdrew: Other277288
Withdrew: Treatment refusal113208
Withdrew: Randomized but not treated4654
Withdrew: Protocol violation2391
Withdrew: Intercurrent illness1729
Withdrew: Too early switch0103
Withdrew: No/too late switch/refusal to switch0750

Outcome measures

PrimaryDisease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years

Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.

Time frame:
Baseline (Month 0) up to 2.75 years
Reported as:
Number · Events (disease relapse or death)
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years
Events (disease relapse or death)ExemestaneTamoxifen Followed by Exemestane
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years352388
Statistical analysis
  • Exemestane vs Tamoxifen Followed by Exemestane · Log Rank · p = 0.118 · Hazard ratio (hr): 0.89 · 95% CI 0.77 to 1.03A hazard ratio less than 1 favors the test treatment (exemestane only arm).
PrimaryDisease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years

Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.

Time frame:
Baseline (Month 0) up to 5 years
Reported as:
Number · Events (disease relapse or death)
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years
Events (disease relapse or death)ExemestaneTamoxifen Followed by Exemestane
Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years712714
Statistical analysis
  • Exemestane vs Tamoxifen Followed by Exemestane · Log Rank · p = 0.604 · Hazard ratio (hr): 0.97 · 95% CI 0.88 to 1.08A hazard ratio less than 1 favors the test treatment (exemestane only arm).
SecondaryNumber of Events for Overall Survival (OS)

Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.

Time frame:
Baseline (Month 0) up to 5 years
Reported as:
Number · Events (death)
Number of Events for Overall Survival (OS)
Events (death)ExemestaneTamoxifen Followed by Exemestane
Number of Events for Overall Survival (OS)485476
Statistical analysis
  • Exemestane vs Tamoxifen Followed by Exemestane · Log Rank · p = 0.951 · Hazard ratio (hr): 1.00 · 95% CI 0.89 to 1.14A hazard ratio less than 1 favors the test treatment (exemestane only arm).
SecondaryTime to New Primary Breast Cancers

New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).

Time frame:
Baseline (Month 0) up to 5 years

No measurements were reported for this outcome.

SecondaryNumber of Events for Time to Relapse

Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.

Time frame:
Baseline (Month 0) up to 5 years
Reported as:
Number · Events (disease relapse)
Number of Events for Time to Relapse
Events (disease relapse)ExemestaneTamoxifen Followed by Exemestane
Number of Events for Time to Relapse499521
Statistical analysis
  • Exemestane vs Tamoxifen Followed by Exemestane · Log Rank · p = 0.293 · Hazard ratio (hr): 0.94 · 95% CI 0.83 to 1.06A hazard ratio less than 1 favors the test treatment (exemestane only arm).
SecondaryNumber of Participants With New Primary Non-breast Cancers

Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.

Time frame:
Baseline (Month 0) up to 5 years
Reported as:
Number · Participants
Number of Participants With New Primary Non-breast Cancers
ParticipantsExemestaneTamoxifen Followed by Exemestane
Colorectal cancer4332
Lung cancer2417
Endometrial cancer717
DCIS34
Other primary cancer types110106

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tamoxifen Followed by Exemestane—784/4,814 (16.3%)3,551/4,814 (73.8%)
Exemestane—831/4,852 (17.1%)3,567/4,852 (73.5%)
Most frequent serious events
Showing 10 of 734
Most frequent serious events
EventTamoxifen Followed by ExemestaneExemestane
OsteoarthritisMusculoskeletal and connective tissue disorders14/481434/4852
DyspnoeaRespiratory, thoracic and mediastinal disorders13/481428/4852
FractureInjury, poisoning and procedural complications15/481427/4852
PneumoniaInfections and infestations26/481425/4852
Cerebrovascular accidentNervous system disorders20/481426/4852
Pulmonary embolismRespiratory, thoracic and mediastinal disorders22/481424/4852
Myocardial infarctionCardiac disorders18/481418/4852
Atrial fibrillationCardiac disorders15/481418/4852
Endometrial hyperplasiaReproductive system and breast disorders17/48140/4852
Chest painGeneral disorders15/481416/4852
Most frequent other events
Showing 10 of 64
Most frequent other events
EventTamoxifen Followed by ExemestaneExemestane
Hot flushVascular disorders1690/48141517/4852
ArthralgiaMusculoskeletal and connective tissue disorders1002/48141157/4852
FatigueGeneral disorders800/4814796/4852
InsomniaPsychiatric disorders452/4814549/4852
PainGeneral disorders492/4814541/4852
NauseaGastrointestinal disorders482/4814419/4852
OsteoporosisMusculoskeletal and connective tissue disorders219/4814428/4852
DepressionPsychiatric disorders417/4814404/4852
Weight increasedInvestigations415/4814339/4852
HeadacheNervous system disorders372/4814369/4852

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ExemestaneTamoxifen Followed by ExemestaneTotal
Mean65 ± 964 ± 964 ± 9
Age, Customized
Age, Customized(Participants)ExemestaneTamoxifen Followed by ExemestaneTotal
Less than 50 years171160331
50 to 59 years151015073017
60 to 69 years183518963731
Greater than and equal to 70 years138213052687
Sex: Female, Male
Sex: Female, Male(Participants)ExemestaneTamoxifen Followed by ExemestaneTotal
Female489848689766
Male000
08

Study locations

179 sites
  • Pfizer Investigational Site
    Bessemer, Alabama 35022, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35205, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35209, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35211, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35213, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35235, United States
  • Pfizer Investigational Site
    Flagstaff, Arizona 86001, United States
  • Pfizer Investigational Site
    Green Valley, Arizona 85614, United States
  • Pfizer Investigational Site
    Oro Valley, Arizona 85737, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85012, United States
  • Pfizer Investigational Site
    Safford, Arizona 85546, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona 85258, United States
  • Pfizer Investigational Site
    Sedona, Arizona 86336, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85710, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85745, United States
  • Pfizer Investigational Site
    Tuscon, Arizona 85704, United States
  • Pfizer Investigational Site
    North Little Rock, Arkansas 72117, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Boulder, Colorado 80303, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Pfizer Investigational Site
    Denver, Colorado 80218, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Fort Collins, Colorado *0524, United States
  • Pfizer Investigational Site
    Lakewood, Colorado 80228, United States
  • Pfizer Investigational Site
    Lone Tree, Colorado 80124, United States
  • Pfizer Investigational Site
    Longmont,, Colorado 80501, United States
  • Pfizer Investigational Site
    Pueblo, Colorado 81008, United States
  • Pfizer Investigational Site
    Thornton, Colorado 80260-, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    Hudson,, Florida 34667, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32204, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32207, United States
  • Pfizer Investigational Site
    Lauderhill, Florida 33319, United States
  • Pfizer Investigational Site
    Melbourne, Florida 32901, United States
  • Pfizer Investigational Site
    New Port Richey, Florida 34655, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Orange Park, Florida 32073, United States
  • Pfizer Investigational Site
    Palatka, Florida 32177, United States
  • Pfizer Investigational Site
    Plantation, Florida 33324, United States
  • Pfizer Investigational Site
    St Augustine, Florida 32086, United States
  • Pfizer Investigational Site
    Alton,, Illinois 62002, United States
  • Pfizer Investigational Site
    Arlington Heights, Illinois �60005, United States
  • Pfizer Investigational Site
    Niles, Illinois 60714, United States
  • Pfizer Investigational Site
    Winfield, Illinois 60190, United States
  • Pfizer Investigational Site
    Carmel, Indiana 46032, United States
  • Pfizer Investigational Site
    Fishers, Indiana 46037, United States
  • Pfizer Investigational Site
    Greenfield, Indiana 46140, United States
  • Pfizer Investigational Site
    Indianapolis,, Indiana 46227, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46219, United States
  • Pfizer Investigational Site
    Shelbyville, Indiana 46176, United States
  • Pfizer Investigational Site
    Terre Haute, Indiana 47802, United States
  • Pfizer Investigational Site
    Cedar Rapids, Iowa 52403, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66112, United States
  • Pfizer Investigational Site
    Shawnee Mission, Kansas 66204, United States
  • Pfizer Investigational Site
    Westminster, Maryland 21157, United States
  • Pfizer Investigational Site
    North Adams, Massachusetts 01247, United States
  • Pfizer Investigational Site
    Pittsfield, Massachusetts 01201, United States
  • Pfizer Investigational Site
    Burnsville, Minnesota 55337, United States
  • Pfizer Investigational Site
    Edina, Minnesota 55435-2150, United States
  • Pfizer Investigational Site
    Maplewood, Minnesota 55109, United States
  • Pfizer Investigational Site
    St. Paul, Minnesota 55102-2389, United States
  • Pfizer Investigational Site
    Woodbury,, Minnesota 55125, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65201, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64111, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64131, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64154, United States
  • Pfizer Investigational Site
    Lee's summit, Missouri 29307, United States
  • Pfizer Investigational Site
    Lee's Summit, Missouri 64064, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63136, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89128, United States
  • Pfizer Investigational Site
    Santa Fe, New Mexico 87505, United States
  • Pfizer Investigational Site
    Albany,, New York 12208, United States
  • Pfizer Investigational Site
    Albany, New York 12206, United States
  • Pfizer Investigational Site
    Amsterdam,, New York 12010, United States
  • Pfizer Investigational Site
    Brockport, New York 14420, United States
  • Pfizer Investigational Site
    Canandaigua, New York 14424, United States
  • Pfizer Investigational Site
    Geneva, New York 14456, United States
  • Pfizer Investigational Site
    Hudson, New York 12534, United States
  • Pfizer Investigational Site
    Latham, New York 12110-0610, United States
  • Pfizer Investigational Site
    Rexford,, New York 12148, United States
  • Pfizer Investigational Site
    Troy,, New York 12180, United States
  • Pfizer Investigational Site
    Asheville, North Carolina 28801, United States
  • Pfizer Investigational Site
    Cary, North Carolina 27518, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27704, United States
  • Pfizer Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • Pfizer Investigational Site
    Hickory, North Carolina 28602, United States
  • Pfizer Investigational Site
    Kernersville, North Carolina 27284, United States
  • Pfizer Investigational Site
    Lexington, North Carolina 27295, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27607, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27614, United States
  • Pfizer Investigational Site
    Seneca, North Carolina 29672, United States
  • Pfizer Investigational Site
    Winston-salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Kettering, Ohio 45409, United States
  • Pfizer Investigational Site
    Bartlesville, Oklahoma 74006, United States
  • Pfizer Investigational Site
    Noman, Oklahoma 73071, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73102, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73104-5020, United States
  • Pfizer Investigational Site
    Oklahoma city, Oklahoma 73109, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112-4416, United States

Showing the first 100 of 179 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, Duijm-de Carpentier M, Rutgers EJT, Seynaeve C, Bartlett JMS, Vannetzel JM, Rea DW, Hasenburg A, Paridaens R, Markopoulos CJ, Hozumi Y, Portielje JEA, Kroep JR, van de Velde CJH, Liefers GJ. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. J Clin Oncol. 2020 Oct 1;38(28):3273-3281. doi: 10.1200/JCO.19.02427. Epub 2020 Jul 24. PubMed 32706636 ↗
  • Bayani J, Kornaga EN, Crozier C, Jang GH, Bathurst L, Kalatskaya I, Trinh QM, Yao CQ, Livingstone J, Boutros PC, Spears M, McPherson JD, Stein LD, Rea D, Bartlett JMS. Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00373. PubMed 35100692 ↗
  • Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6. PubMed 29885375 ↗
  • Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3. PubMed 24091623 ↗
  • van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4. PubMed 21247627 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001, a primary completion of Oct 2008 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2002
First posted
May 9, 2002
Start
Aug 2001
Primary completionActual
Oct 2008
CompletionActual
Feb 2011
Results first posted
Dec 4, 2009
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00036270
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 9, 2002
Start date
Aug 2001
Primary completion
Oct 2008
Completion
Feb 2011
Results posted
Dec 4, 2009
Last update
Oct 28, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exemestane · Tamoxifen

Start the discussion